PALVELLA THERAPEUTICS, INC. 8K

Palvella Therapeutics furnished a July 2026 corporate presentation detailing its QTORIN rare disease pipeline, rolling NDA and commercialization plans for QTORIN rapamycin in microcystic lymphatic malformations, expansion into additional indications, and funding from a recent $230 million financing.

Palvella Therapeutics, Inc. furnished an investor presentation dated July 2026 outlining its development and commercialization strategy for its QTORIN platform, highlighting positive Phase 3 SELVA data for QTORIN 3.9% rapamycin gel in microcystic lymphatic malformations and progress toward a rolling New Drug Application submission targeted for completion in the second half of 2026 with a potential first-half 2027 FDA approval and U.S. launch, advancement of QTORIN programs in cutaneous venous malformations, clinically significant angiokeratomas, and disseminated superficial actinic porokeratosis, expansion of commercial planning including a rare disease–focused sales force, and its capital position following a $230 million oversubscribed financing in Q1 2026 intended to fund key regulatory and clinical milestones.

Filing Facts

CIK

1583648

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-303307

Alert Tier

6